TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Neurimmune to Regain Global Rights for Brain Amyloid Depleter in Alzheimer’s Disease Treatment

Thursday, February 01, 2024

Neurimmune has recently announced the regaining of global rights to aducanumab, a recombinant human antibody designed to reduce brain amyloid and granted FDA accelerated approval for the treatment of Alzheimer’s disease. The antibody was initially licensed to Biogen in 2007, and Neurimmune now holds the global rights following the termination of the collaboration by Biogen. In addition to gaining intellectual property rights, Neurimmune will also acquire access to clinical data, GMP supplies, and manufacturing technology associated with aducanumab.

Alzheimer’s disease, the primary cause of dementia in the elderly, is characterized by the prolonged accumulation of the protein amyloid in the brain. Aducanumab, as the first in its antibody class, has demonstrated significant reduction in brain amyloid, leading to a noticeable slowdown in clinical decline. Christoph Hock, Neurimmune's Chief Medical Officer, emphasized the validated therapeutic target of amyloid depletion in the treatment of Alzheimer’s.

The effectiveness of aducanumab extends to reducing tau pathology, providing additional evidence of its disease-modifying effect. Tau pathology, induced by brain amyloid, can damage neuronal transport systems, resulting in neurofibrillary tangles and cognitive decline. Neurimmune is now positioned to lead the future development of aducanumab, with a specific focus on early intervention through subcutaneous administrations. Fabian Buller, Chief Business Officer of Neurimmune, expressed excitement about advancing aducanumab-based therapeutics and committed to providing updates on the progress made.



patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit